See more : Cistera Networks, Inc. (CNWT) Income Statement Analysis – Financial Results
Complete financial analysis of Aptose Biosciences Inc. (APTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aptose Biosciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cochlear Limited (CHEOY) Income Statement Analysis – Financial Results
- Money Partners Group Co.,Ltd. (8732.T) Income Statement Analysis – Financial Results
- Origin Materials, Inc. (ORGNW) Income Statement Analysis – Financial Results
- ABB Ltd (ABBN.SW) Income Statement Analysis – Financial Results
- China Merchants Land Limited (0978.HK) Income Statement Analysis – Financial Results
Aptose Biosciences Inc. (APTO)
About Aptose Biosciences Inc.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 124.16K | 168.81K | 43.02K | 100.02K | 24.00K | 5.00K | 446.69K | 47.82K | 0.00 | 1.00K | 667.40 | 67.82K | 68.65K | 72.56K |
| Cost of Revenue | 474.55K | 507.08K | 616.53K | 646.44K | 627.25K | 83.51K | 89.09K | 114.84K | 69.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 15.00K | 3.00K | 1.00K | 20.99K | 39.85K | 0.00 | -1.17M | -945.71K | -203.46K | -68.65K | 0.00 |
| Gross Profit | -474.55K | -507.08K | -616.53K | -646.44K | -627.25K | -83.51K | -89.09K | -114.84K | -69.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 124.16K | 168.81K | 41.02K | 85.02K | 21.00K | 4.00K | 425.71K | 7.97K | 0.00 | 1.17M | 946.37K | 271.28K | 137.31K | 72.56K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 95.35% | 85.00% | 87.50% | 79.99% | 95.30% | 16.67% | 0.00% | 117,163.13% | 141,800.00% | 400.00% | 200.00% | 100.00% |
| Research & Development | 36.77M | 28.09M | 45.99M | 29.29M | 16.84M | 18.73M | 6.27M | 7.68M | 4.51M | 3.56K | 2.78M | 3.22M | 1.93M | 2.35M | 2.39M | 3.45M | 6.12M | 3.16M | 9.30M | 11.47M | 19.66M | 9.14M | 5.67M | 6.37M | 2.83M | 2.17M | 1.92M | 2.10M |
| General & Administrative | 15.59M | 14.43M | 19.32M | 26.35M | 9.90M | 10.32M | 5.50M | 6.13M | 7.05M | 8.20K | 6.07M | 2.20M | 2.49M | 2.69M | 2.98M | 3.12M | 3.89M | 3.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 745.45K | 219.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.59M | 14.43M | 19.32M | 26.35M | 9.90M | 10.32M | 5.50M | 6.13M | 7.05M | 8.20K | 6.07M | 2.20M | 2.49M | 2.69M | 2.98M | 3.12M | 4.63M | 4.07M | 5.03M | 5.44M | 3.61M | 3.13M | 3.18M | 4.17M | 2.44M | 1.15M | 1.30M | 1.09M |
| Other Expenses | 0.00 | 81.00K | 138.00K | 135.00K | 122.00K | 53.00K | 50.00K | 79.61K | 48.28K | 0.00 | 4.61K | 4.85K | 217.37K | 57.33K | 81.51K | 173.39K | 319.17K | 479.11K | 779.02K | 0.00 | 307.79K | 0.00 | 1.28M | 2.41M | 1.78M | 203.46K | 274.61K | 362.79K |
| Operating Expenses | 52.36M | 42.60M | 65.45M | 55.77M | 26.86M | 29.11M | 11.83M | 13.89M | 11.60M | 11.83K | 8.85M | 5.42M | 4.46M | 5.10M | 5.44M | 6.74M | 11.07M | 7.71M | 15.11M | -17.35M | 23.58M | -13.00M | 10.13M | 12.95M | 7.05M | 3.53M | 3.50M | 3.56M |
| Cost & Expenses | 52.36M | 42.60M | 65.45M | 55.77M | 26.86M | 29.11M | 11.83M | 13.89M | 11.60M | 11.83K | 8.85M | 5.42M | 4.46M | 5.10M | 5.44M | 6.74M | 11.08M | 7.73M | 15.11M | -17.35M | 23.60M | -12.96M | 10.13M | 11.78M | 6.10M | 3.32M | 3.43M | 3.56M |
| Interest Income | 1.15M | 788.00K | 94.00K | 522.00K | 574.00K | 283.00K | 165.00K | 78.12K | 206.10K | 327.15 | 70.04K | 29.11K | 5.82K | 72.68K | 19.90K | 247.71K | 545.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.10K | 30.99K | 0.00 | 238.69K | 5.82K | 19.41K | 14.33K | 51.18K | 648.62K | 1.03M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 88.00K | 507.08K | 616.53K | 646.44K | 627.25K | 83.51K | 89.09K | 114.84K | 48.28K | 32.57 | 19.35K | 36.87K | 42.70K | 57.33K | 81.51K | 173.39K | 319.17K | 1.09M | 2.21M | 1.87M | 1.59M | 1.48M | 2.42M | 2.41M | 1.78M | 339.10K | 274.61K | 362.79K |
| EBITDA | -52.27M | -39.66M | -64.16M | -57.51M | -26.26M | -27.31M | -11.61M | -13.78M | -10.43M | -11.73M | -9.46M | -5.34M | -4.39M | -5.02M | -5.64M | -5.71M | -3.84M | -6.53M | -12.88M | -15.20M | -21.56M | 14.49M | -7.71M | -9.37M | -4.32M | -2.98M | -3.09M | -3.12M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12,597.00% | -3,108.70% | -36,881.21% | -5,659.01% | -50,680.50% | 391,383.67% | -4,826.63% | 30,300.39% | 0.00% | -936,904.62% | -647,800.00% | -4,400.00% | -4,500.00% | -4,300.02% |
| Operating Income | -52.36M | -42.59M | -65.45M | -55.78M | -26.86M | -29.11M | -11.83M | -13.89M | -11.60M | -11.76K | -8.85M | -5.42M | -4.46M | -5.10M | -5.32M | -6.57M | -11.03M | -7.63M | -15.09M | 17.36M | -23.15M | 13.01M | -10.13M | -11.78M | -6.10M | -3.26M | -3.36M | -3.56M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,283.99% | -3,894.57% | -25,646.38% | -7,624.01% | -62,859.99% | 347,225.52% | -5,182.56% | 27,202.43% | 0.00% | -1,177,628.74% | -914,000.00% | -4,800.00% | -4,900.00% | -4,900.03% |
| Total Other Income/Expenses | 1.15M | 779.00K | 93.00K | 530.00K | 580.00K | 239.00K | 165.00K | 60.60K | 1.06M | 259.05 | -870.90K | 23.29K | -36.51K | -58.83K | 10.40M | 0.00 | 0.00 | -1.39M | -1.49M | 17.42M | 909.38K | -25.13M | 1.31M | 1.88M | 361.06K | 202.78K | 137.31K | 0.00 |
| Income Before Tax | -51.21M | -41.82M | -65.35M | -55.24M | -26.28M | -28.87M | -11.66M | -13.86M | -10.54M | -11.50K | -9.73M | -5.40M | -4.48M | -5.16M | 5.05M | -8.13M | -6.37M | -9.01M | -16.27M | -17.58M | -22.24M | -12.12M | -8.83M | -9.89M | -5.74M | -3.12M | -3.23M | -3.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4,069.48% | -4,815.23% | -14,806.90% | -9,010.01% | -67,772.62% | -351,705.34% | -4,978.98% | -25,341.99% | 0.00% | -989,188.23% | -859,900.00% | -4,600.00% | -4,700.00% | -4,800.03% |
| Income Tax Expense | 0.00 | -770.00K | -93.00K | -530.00K | -580.00K | -44.00K | 97.00K | -35.23K | 30.99K | 0.00 | 238.69K | -5.39M | 4.48M | 5.16M | -5.05M | 8.13M | 6.37M | 9.01M | 16.27M | 17.58M | 22.24M | 12.12M | 8.83M | 9.89M | 5.74M | 3.12M | 3.23M | 3.48M |
| Net Income | -51.21M | -41.05M | -65.26M | -54.71M | -25.70M | -28.87M | -11.66M | -13.86M | -10.54M | -11.50K | -9.73M | -5.40M | -4.48M | -5.16M | 5.05M | -8.13M | -6.37M | -9.01M | -16.27M | -17.58M | -22.24M | -12.12M | -8.83M | -9.89M | -5.74M | -3.12M | -3.23M | -3.48M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4,069.48% | -4,815.23% | -14,806.90% | -9,010.01% | -67,772.62% | -351,705.34% | -4,978.98% | -25,341.99% | 0.00% | -989,188.23% | -859,900.00% | -4,600.00% | -4,700.00% | -4,800.03% |
| EPS | -7.58 | -6.67 | -10.99 | -10.03 | -7.68 | -12.97 | -7.84 | -16.32 | -13.29 | -0.01 | -12.58 | -23.00 | -38.27 | -92.10 | 97.24 | -177.65 | -159.94 | -237.56 | -506.19 | -551.63 | -699.79 | -452.63 | -332.17 | -379.57 | -719.71 | -445.04 | -481.96 | -626.97 |
| EPS Diluted | -7.58 | -6.67 | -10.99 | -10.03 | -7.68 | -12.97 | -7.84 | -16.31 | -13.28 | -0.01 | -12.57 | -23.00 | -38.15 | -91.64 | 97.24 | -177.65 | -159.94 | -237.56 | -506.19 | -551.63 | -699.79 | -452.63 | -332.17 | -379.57 | -719.71 | -445.04 | -481.96 | -626.97 |
| Weighted Avg Shares Out | 6.76M | 6.15M | 5.94M | 5.46M | 3.34M | 2.23M | 1.49M | 849.00K | 793.00K | 773.00K | 773.00K | 234.73K | 117.00K | 56.00K | 52.02K | 45.76K | 39.83K | 37.94K | 32.13K | 31.87K | 31.78K | 26.78K | 26.57K | 26.07K | 7.97K | 7.01K | 6.70K | 5.56K |
| Weighted Avg Shares Out (Dil) | 6.76M | 6.15M | 5.94M | 5.46M | 3.34M | 2.23M | 1.49M | 849.53K | 793.73K | 773.67K | 773.67K | 234.73K | 117.37K | 56.28K | 52.11K | 45.76K | 39.83K | 37.94K | 32.13K | 31.87K | 31.78K | 26.78K | 26.57K | 26.07K | 7.97K | 7.01K | 6.70K | 5.56K |
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
SAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the closing...
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing...
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations Study execution...
Aptose Reports Results for the Third Quarter 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML
Aptose Announces Results from Special Meeting of Shareholders
SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with...
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its...
Aptose Reports Results for the Second Quarter 2024
TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy for Newly Diagnosed AML has been Submitted to the 2025 Annual...
Aptose Announces Receipt of Deficiency Notice from Nasdaq
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it...
Source: https://incomestatements.info
Category: Stock Reports